- Home
- NXL vs TPCS Comparison
NXL vs TPCS Comparison
Compare NXL & TPCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXL
- TPCS
- Stock Information
- Founded
- NXL 2010
- TPCS 1956
- Country
- NXL United States
- TPCS United States
- Employees
- NXL N/A
- TPCS N/A
- Industry
- NXL Medical Specialities
- TPCS Metal Fabrications
- Sector
- NXL Health Care
- TPCS Industrials
- Exchange
- NXL Nasdaq
- TPCS Nasdaq
- Market Cap
- NXL 31.1M
- TPCS N/A
- IPO Year
- NXL 2022
- TPCS N/A
- Fundamental
- Price
- NXL $1.94
- TPCS $2.29
- Analyst Decision
- NXL Strong Buy
- TPCS
- Analyst Count
- NXL 1
- TPCS 0
- Target Price
- NXL $5.00
- TPCS N/A
- AVG Volume (30 Days)
- NXL 124.0K
- TPCS 38.1K
- Earning Date
- NXL 03-14-2025
- TPCS 01-21-2025
- Dividend Yield
- NXL N/A
- TPCS N/A
- EPS Growth
- NXL N/A
- TPCS N/A
- EPS
- NXL N/A
- TPCS N/A
- Revenue
- NXL $168,721.00
- TPCS $33,182,059.00
- Revenue This Year
- NXL $175.37
- TPCS N/A
- Revenue Next Year
- NXL $334.78
- TPCS N/A
- P/E Ratio
- NXL N/A
- TPCS N/A
- Revenue Growth
- NXL 52.35
- TPCS 6.44
- 52 Week Low
- NXL $0.53
- TPCS $2.12
- 52 Week High
- NXL $4.49
- TPCS $5.95
- Technical
- Relative Strength Index (RSI)
- NXL 37.77
- TPCS 35.56
- Support Level
- NXL $2.16
- TPCS $2.12
- Resistance Level
- NXL $2.57
- TPCS $2.49
- Average True Range (ATR)
- NXL 0.22
- TPCS 0.22
- MACD
- NXL -0.00
- TPCS -0.02
- Stochastic Oscillator
- NXL 9.52
- TPCS 20.99
Stock Price Comparison Chart: NXL vs TPCS
■ NXL
■ TPCS
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
Share on Social Networks:
0